



1626

CASE CT-2645 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Samuel J. DuBoff
Type or print name

Samuel J. DuBoff
Signature

January 28, 2003
Date

FEB 06 2003

TECH CENTER 1600/2900

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
YU ET AL.

EXAMINER: REBECCA L. ANDERSON

ART UNIT: 1626

APPLICATION NO: 09/994,012

FILED: NOVEMBER 16, 2001

FOR: HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE
ANTIVIRAL AGENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In follow-up to your telephone call of January 28, 2003, I am faxing to you as requested replacement copies of references AT, AZ, AX, BA and BB (copy of IDS Form PTO-1449 attached for ease of reference) which were previously submitted February 7, 2002. A hard copy of these references will also be mailed to you.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(203) 677-7787
Date: 1/28/03


Samuel J. DuBoff
Samuel J. DuBoff
Attorney for Applicants
Reg. No. 25,969

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT-2645 NP
APPLICATION NO.
09/994,012
APPLICANT
YU ET AL.
FILING DATE
November 16, 2001

Sheet 1 of 2

RECEIVED
FEB 06 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,324,794	4/13/82	R. R. Tidwell, et al			
	AB	5,256,668	10/26/93	K.-H. L. Hsu, et al			
	AC	3,394,141	7/23/68	F. Sparatore			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AJ	EP 058146A1	8/18/82	US Patent 4,525,358 English <i>Equivalent</i>			<input type="checkbox"/>	<input type="checkbox"/>
	AK	AU-A-14,704	12/22/98	US Patent 5,852,015 English <i>Equivalent</i>			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 01/36395	5/25/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 00/38508	7/6/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01/00611	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 01/00612	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 01/00615	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 00/04900	2/3/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	E. J. Dubovi, et al, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 19(4), pp. 649-656, 1981
AS	P. R. Wyde, et al, ANTIVIRAL RESEARCH, 38, pp. 31-42, 1998
AT	F. Pagani, et al, BOLL. CHIM. FARM., 104, pp. 427-431, 1965

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


INFORMATION DISCLOSURE CITATION

Use several sheets if necessary

ATTY. DOCKET NO.
CT-2645 NP
APPLICATION NO.
09/994,012
APPLICANT
YU ET AL.
FILING DATE
November 16, 2001

Sheet 2 of 2

RECEIVED
FEB 06 2003
Group
TECH CENTER 1600/2900



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AU	G. Paglietti, et al, IL. FARMACO-ED. SC., 30 , pp. 505-511, 1975
AV	S. Shigeta, et al, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 3(3) , pp. 171-177, 1992
AW	W. R. Roderick, et al, J. MED. CHEM., 15(6) , pp. 655-658, 1972
AX	B. Cakir, et al, GAZI ECZACILIK FAK. DER., 5(1) , pp. 71-77, 1988
AY	H. R. Howard, et al, EUR. J. MED. CHEM., 27 , pp. 779-789, 1992
AZ	F. Sparatore, et al, IL FARMACO ED. SCI., 33 , pp. 901-923, 1978
BA	JAMA, 277(1) , pp. 12-13, 1997
BB	E. De Clercq, INT. J. ANTIMICROBIAL AGENTS, 7 , pp. 193-202, 1996
BC	R. R. Tidwell, et al, J. MED. CHEM., 26 , pp. 294-298, 1983
BD	
BE	
BF	
BG	
BH	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.